Effects of icariside II ameliorates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by activating Akt/NOS/NF-κB signaling

Yang,Lu; Peng,Chaosheng; Xia,Jing; Zhang,Wenluo; Tian,Li; Tian,Yuhong; Yang,Xiaobin; Cao,Yuean

doi:10.3892/mmr.2017.8342

Effects of icariside II ameliorates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by activating Akt/NOS/NF-κB signaling

Authors:
- Lu Yang
- Chaosheng Peng
- Jing Xia
- Wenluo Zhang
- Li Tian
- Yuhong Tian
- Xiaobin Yang
- Yuean Cao
View Affiliations

Affiliations: Special Care Medical Center, Navy General Hospital of PLA, Beijing 100048, P.R. China
Published online on: December 22, 2017 https://doi.org/10.3892/mmr.2017.8342
Pages: 4099-4105

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Icariside II is a flavonoid extracted from Epimedium that has antioxidant, anti‑inflammatory and antiapoptotic effects. The aim of the present study was to evaluate the effects icariside II on diabetic cardiomyopathy in streptozotocin-induced diabetic rats. Icariside II treatment improved body weight, heart/body weight ratio and fasting blood glucose in diabetic model rats. Icariside II was demonstrated to reduce the expression levels of creatine kinase and lactate dehydrogenase in serum, and to lower cardiac oxidative stress, inflammation and apoptosis levels in diabetic rats. Icariside II treatment induced phosphoinositide 3‑kinase and phosphorylated‑Akt expression, and suppressed inducible nitric oxide synthase (iNOS) and nuclear factor (NF)‑κB protein expression in diabetic rat. Results from the present study suggested that treatment with icariside II improved diabetic cardiomyopathy in streptozotocin‑induced diabetic rats by activating the Akt/NOS/NF‑κB pathway.

View Figures

View References

1	Agrawal V, Agrawal A, Dwivedi AN and Tripathi K: Correlation between 2D echocardiography and multidetector row CT for early detection of diastolic dysfunction in normotensive diabetic patients. J Clin Diagn Res. 10:OC27–30. 2016.PubMed/NCBI
2	Ding Y, Wang Y, Chen J, Hu Y, Cao Z, Ren P and Zhang Y: p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumour Biol. 35:3119–3123. 2014. View Article : Google Scholar : PubMed/NCBI
3	Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P and Valensi P: Evidence for a specific diabetic cardiomyopathy: An observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol. 7435032015.PubMed/NCBI
4	Zhuo C, Jiang R, Lin X and Shao M: LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 8:1429–1437. 2017. View Article : Google Scholar : PubMed/NCBI
5	Holscher ME, Bode C and Bugger H: Diabetic Cardiomyopathy: Does the type of diabetes matter? Int J Mol Sci. 17:21362016. View Article : Google Scholar :
6	Xu G, Kuang G, Jiang W, Jiang R and Jiang D: Polydatin promotes apoptosis through upregulation the ratio of Bax/Bcl-2 and inhibits proliferation by attenuating the beta-catenin signaling in human osteosarcoma cells. Am J Transl Res. 8:922–931. 2016.PubMed/NCBI
7	Li Z, Zhang J, Mulholland M and Zhang W: mTOR activation protects liver from ischemia/reperfusion-induced injury through NF-kappaB pathway. FASEB J. 31:3016–3026. 2017. View Article : Google Scholar
8	Korkmaz-Icöz S, Al Said S, Radovits T, Li S, Brune M, Hegedűs P, Atmanli A, Ruppert M, Brlecic P, Lehmann LH, et al: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway. Cardiovasc Diabetol. 15:752016. View Article : Google Scholar : PubMed/NCBI
9	Zhang H, Xiong Z, Wang J, Zhang S, Lei L, Yang L and Zhang Z: Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway. Mol Med Rep. 13:1593–1601. 2016. View Article : Google Scholar : PubMed/NCBI
10	He H, Qiao X and Wu S: Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy. Exp Ther Med. 6:567–573. 2013. View Article : Google Scholar : PubMed/NCBI
11	Thomas CM, Yong QC, Rosa RM, Seqqat R, Gopal S, Casarini DE, Jones WK, Gupta S, Baker KM and Kumar R: Cardiac-specific suppression of NF-kappaB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am J Physiol Heart Circ Physiol. 307:H1036–1045. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wang ZQ, Chen MT, Zhang R, Zhang Y, Li W and Li YG: Docosahexaenoic acid attenuates doxorubicin-induced cytotoxicity and inflammation by suppressing NF-kappaB/iNOS/NO signaling pathway activation in H9C2 cardiac cells. J Cardiovasc Pharmacol. 67:283–289. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ren XM, Zuo GF, Wu W, Luo J, Ye P, Chen SL and Hu ZY: Atorvastatin alleviates experimental diabetic cardiomyopathy by regulating the GSK-3beta-PP2Ac-NF-kappaB signaling axis. PLoS One. 11:e01667402016. View Article : Google Scholar : PubMed/NCBI
14	Yin C, Deng Y, Gao J, Li X, Liu Y and Gong Q: Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats. Neuroscience. 328:69–79. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tian W, Lei H, Guan R, Xu Y, Li H, Wang L, Yang B, Gao Z and Xin Z: Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Drug Des Devel Ther. 9:5147–5157. 2015.PubMed/NCBI
16	Frustaci A, Ciccosanti F, Chimenti C, Nardacci R, Corazzari M, Verardo R, Ippolito G, Petrosillo N, Fimia GM and Piacentini M: Histological and proteomic profile of diabetic versus non-diabetic dilated cardiomyopathy. Int J Cardiol. 203:282–289. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhu Z and Hu X: HMGB1 induced endothelial permeability promotes myocardial fibrosis in diabetic cardiomyopathy. Int J Cardiol. 227:8752017. View Article : Google Scholar : PubMed/NCBI
18	Lebeche D: Diabetic cardiomyopathy: is resistin a culprit? Cardiovasc Diagn Ther. 5:387–393. 2015.PubMed/NCBI
19	Wu H, Sheng ZQ, Xie J, Li R, Chen L, Li GN, Wang L and Xu B: Reduced HMGB 1-mediated pathway and oxidative stress in resveratrol-treated diabetic mice: A possible mechanism of cardioprotection of resveratrol in diabetes mellitus. Oxid Med Cell Longev. 2016:98368602016. View Article : Google Scholar : PubMed/NCBI
20	Kuo WW, Wang WJ, Tsai CY, Way CL, Hsu HH and Chen LM: Diallyl trisufide (DATS) suppresses high glucose-induced cardiomyocyte apoptosis by inhibiting JNK/NFkappaB signaling via attenuating ROS generation. Int J Cardiol. 168:270–280. 2013. View Article : Google Scholar : PubMed/NCBI
21	Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P and Pacher P: Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta. 1852:232–242. 2015. View Article : Google Scholar : PubMed/NCBI
22	Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T, Katoh D, Nagoshi T, Tojo K, Minamino T, et al: Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes. 64:618–630. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhao YZ, Zhang M, Wong HL, Tian XQ, Zheng L, Yu XC, Tian FR, Mao KL, Fan ZL, Chen PP, et al: Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. J Control Release. 223:11–21. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yu W, Zha W, Guo S, Cheng H, Wu J and Liu C: Flos Puerariae extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice. PLoS One. 9:e980442014. View Article : Google Scholar : PubMed/NCBI
25	Zhang L, Ding WY, Wang ZH, Tang MX, Wang F, Li Y, Zhong M, Zhang Y and Wei Zhang: Erratum to: Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 14:3092016. View Article : Google Scholar : PubMed/NCBI
26	Wu MP, Zhang YS, Zhou QM, Xiong J, Dong YR and Yan C: Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of beta2-AR/PI3K/AKT signaling pathway. Pharmacol Res. 104:115–123. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Ji SY, Liu SZ, Jing R and Lou WJ: Cardioprotective effect of breviscapine: Inhibition of apoptosis in H9c2 cardiomyocytes via the PI3K/Akt/eNOS pathway following simulated ischemia/reperfusion injury. Pharmazie. 70:593–597. 2015.PubMed/NCBI
28	Liu W, Mao L, Ji F, Chen F, Wang S and Xie Y: Icariside II activates EGFR-Akt-Nrf2 signaling and protects osteoblasts from dexamethasone. Oncotarget. 8:2594–2603. 2017.PubMed/NCBI
29	Jiang C, Tong YL, Zhang D, Liu LZ and Wang JF: Sinomenine prevents the development of cardiomyopathy in diabetic rats by inhibiting inflammatory responses and blocking activation of NF-kappaB. Gen Physiol Biophys. 36:65–74. 2017. View Article : Google Scholar : PubMed/NCBI
30	Song J, Feng L, Zhong R, Xia Z, Zhang L, Cui L, Yan H, Jia X and Zhang Z: Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-kappaB signaling pathway. Mol Carcinog. 56:36–48. 2017. View Article : Google Scholar : PubMed/NCBI
31	Lee KS, Lee HJ, Ahn KS and Kim SH, Nam D, Kim DK, Choi DY, Ahn KS, Lu J and Kim SH: Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett. 280:93–100. 2009. View Article : Google Scholar : PubMed/NCBI